2017 Q4 Form 10-K Financial Statement
#000143774918004975 Filed on March 19, 2018
Income Statement
| Concept | 2017 Q4 | 2017 | 2016 Q4 |
|---|---|---|---|
| Revenue | $18.89M | $71.08M | $16.85M |
| YoY Change | 12.11% | 0.82% | -10.09% |
| Cost Of Revenue | $6.460M | $18.37M | $5.490M |
| YoY Change | 17.67% | 13.33% | 10.91% |
| Gross Profit | $12.44M | $43.36M | $11.36M |
| YoY Change | 9.51% | -3.08% | -17.62% |
| Gross Profit Margin | 65.85% | 61.01% | 67.42% |
| Selling, General & Admin | $10.17M | $35.01M | $9.850M |
| YoY Change | 3.25% | 2.1% | 2.39% |
| % of Gross Profit | 81.75% | 80.73% | 86.71% |
| Research & Development | |||
| YoY Change | |||
| % of Gross Profit | |||
| Depreciation & Amortization | $1.480M | $6.963M | $10.75M |
| YoY Change | -86.23% | 0.99% | 30.46% |
| % of Gross Profit | 11.9% | 16.06% | 94.63% |
| Operating Expenses | $11.64M | $47.17M | $11.11M |
| YoY Change | 4.77% | 7.78% | 3.83% |
| Operating Profit | $800.0K | -$3.812M | $250.0K |
| YoY Change | 220.0% | -491.38% | -91.91% |
| Interest Expense | -$320.0K | $1.332M | -$330.0K |
| YoY Change | -3.03% | -0.89% | 6.45% |
| % of Operating Profit | -40.0% | -132.0% | |
| Other Income/Expense, Net | $0.00 | -$1.445M | -$20.00K |
| YoY Change | -100.0% | 8.0% | -150.0% |
| Pretax Income | -$1.630M | -$5.257M | -$800.0K |
| YoY Change | 103.75% | 1344.23% | -136.04% |
| Income Tax | -$640.0K | $15.45M | -$330.0K |
| % Of Pretax Income | |||
| Net Earnings | -$17.99M | -$20.71M | -$470.0K |
| YoY Change | 3727.66% | 9227.48% | -130.72% |
| Net Earnings / Revenue | -95.24% | -29.13% | -2.79% |
| Basic Earnings Per Share | -$0.91 | ||
| Diluted Earnings Per Share | -$789.7K | -$0.91 | -$20.77K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 22.78M shares | 22.74M | 22.67M shares |
| Diluted Shares Outstanding | 22.74M |
Balance Sheet
| Concept | 2017 Q4 | 2017 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.500M | $3.469M | $3.400M |
| YoY Change | 2.94% | 2.09% | 325.0% |
| Cash & Equivalents | $3.469M | $3.469M | $3.398M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.150M | $1.150M | $949.0K |
| YoY Change | 21.18% | -68.27% | 10.22% |
| Inventory | $1.764M | $1.764M | $2.166M |
| Prepaid Expenses | |||
| Receivables | $11.28M | $11.28M | $11.58M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $17.67M | $17.67M | $20.77M |
| YoY Change | -14.94% | -14.94% | 9.54% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.633M | $26.57M | $1.997M |
| YoY Change | -18.23% | -16.12% | -15.74% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $24.51M | $31.24M | |
| YoY Change | -21.53% | -0.94% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $131.0K | $131.0K | $225.0K |
| YoY Change | -41.78% | -98.97% | -10.36% |
| Total Long-Term Assets | $51.21M | $51.21M | $75.58M |
| YoY Change | -32.23% | -32.23% | -1.08% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $17.67M | $17.67M | $20.77M |
| Total Long-Term Assets | $51.21M | $51.21M | $75.58M |
| Total Assets | $68.88M | $68.88M | $96.34M |
| YoY Change | -28.51% | -28.51% | 1.04% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $5.516M | $5.516M | $5.315M |
| YoY Change | 3.78% | 3.78% | -19.3% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $3.039M | $3.544M | $5.314M |
| YoY Change | -42.81% | -57.05% | 188.49% |
| Total Short-Term Liabilities | $12.47M | $12.47M | $16.44M |
| YoY Change | -24.12% | -24.12% | 7.75% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $25.35M | $25.39M | $26.58M |
| YoY Change | -4.61% | -12.92% | 0.11% |
| Other Long-Term Liabilities | $7.000K | $7.000K | $66.00K |
| YoY Change | -89.39% | -89.39% | |
| Total Long-Term Liabilities | $37.93M | $25.39M | $29.22M |
| YoY Change | 29.82% | -13.09% | -1.9% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $12.47M | $12.47M | $16.44M |
| Total Long-Term Liabilities | $37.93M | $25.39M | $29.22M |
| Total Liabilities | $37.93M | $37.93M | $45.66M |
| YoY Change | -16.92% | -16.92% | 1.37% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$61.63M | -$41.14M | |
| YoY Change | 49.81% | 0.54% | |
| Common Stock | $2.000K | $2.000K | |
| YoY Change | 0.0% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $30.95M | $30.95M | $50.69M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $68.88M | $68.88M | $96.34M |
| YoY Change | -28.51% | -28.51% | 1.04% |
Cashflow Statement
| Concept | 2017 Q4 | 2017 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$17.99M | -$20.71M | -$470.0K |
| YoY Change | 3727.66% | 9227.48% | -130.72% |
| Depreciation, Depletion And Amortization | $1.480M | $6.963M | $10.75M |
| YoY Change | -86.23% | 0.99% | 30.46% |
| Cash From Operating Activities | $3.620M | $7.718M | $4.170M |
| YoY Change | -13.19% | -2.41% | 151.2% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$120.0K | $104.0K | -$1.800M |
| YoY Change | -93.33% | -38.1% | 109.3% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $350.0K | $3.866M | $1.140M |
| YoY Change | -69.3% | 12.03% | -30.49% |
| Cash From Investing Activities | $230.0K | $918.0K | -$650.0K |
| YoY Change | -135.38% | -117.18% | -183.33% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -1.180M | -8.565M | -1.190M |
| YoY Change | -0.84% | -57200.0% | -54.58% |
| NET CHANGE | |||
| Cash From Operating Activities | 3.620M | 7.718M | 4.170M |
| Cash From Investing Activities | 230.0K | 918.0K | -650.0K |
| Cash From Financing Activities | -1.180M | -8.565M | -1.190M |
| Net Change In Cash | 2.670M | 71.00K | 2.330M |
| YoY Change | 14.59% | -97.25% | -1394.44% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $3.620M | $7.718M | $4.170M |
| Capital Expenditures | -$120.0K | $104.0K | -$1.800M |
| Free Cash Flow | $3.740M | $7.614M | $5.970M |
| YoY Change | -37.35% | -1.64% | 136.9% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2017 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-12-31 | |
| CY2017 | dei |
Document Type
DocumentType
|
10-K | |
| CY2017Q2 | dei |
Entity Public Float
EntityPublicFloat
|
31478640 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Current
CapitalAndOperatingLeasesFutureMinimumPaymentsCurrent
|
1840000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due
CapitalAndOperatingLeasesFutureMinimumPaymentsDue
|
4912000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due In Five Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
191000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due In Four Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInFourYears
|
181000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due In Three Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
695000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due In Two Years
CapitalAndOperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1258000 | |
| CY2017Q4 | infu |
Capital And Operating Leases Future Minimum Payments Due Thereafter
CapitalAndOperatingLeasesFutureMinimumPaymentsDueThereafter
|
747000 | |
| CY2017 | infu |
Concentration Risk Percentage Of Raw Material Purchases From Suppliers Minimum Threshold
ConcentrationRiskPercentageOfRawMaterialPurchasesFromSuppliersMinimumThreshold
|
0.1 | |
| CY2017 | infu |
Cost Of Revenues Pump Depreciation Sales And Disposals
CostOfRevenuesPumpDepreciationSalesAndDisposals
|
9349000 | |
| CY2016 | infu |
Cost Of Revenues Pump Depreciation Sales And Disposals
CostOfRevenuesPumpDepreciationSalesAndDisposals
|
9551000 | |
| CY2017 | infu |
Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
|
11435000 | |
| CY2016 | infu |
Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
|
||
| CY2017 | infu |
Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
|
||
| CY2016 | infu |
Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
|
||
| CY2017 | infu |
Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
|
6500000 | |
| CY2016 | infu |
Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
|
6300000 | |
| CY2017 | infu |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0825 | |
| CY2016 | infu |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.384 | |
| CY2014Q2 | infu |
Employee Stock Ownership Plan Esop Purchase Per Employee Maximum
EmployeeStockOwnershipPlanESOPPurchasePerEmployeeMaximum
|
25000 | |
| CY2017 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001337013 | |
| CY2017 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2018Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
22805775 | |
| CY2017 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2017 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2017 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2017 | dei |
Trading Symbol
TradingSymbol
|
infu | |
| CY2014Q2 | infu |
Employee Stock Purchase Plan Discount Rate
EmployeeStockPurchasePlanDiscountRate
|
0.15 | |
| CY2017 | infu |
Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
|
2.21 | |
| CY2016 | infu |
Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
|
2.73 | |
| CY2017Q1 | infu |
Leverage Ratio
LeverageRatio
|
2.96 | |
| CY2017Q4 | infu |
Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
|
1567000 | |
| CY2016Q4 | infu |
Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
|
1642000 | |
| CY2017Q4 | infu |
Medical Equipment Held For Sale Or Rental Reserves
MedicalEquipmentHeldForSaleOrRentalReserves
|
500000 | |
| CY2016Q4 | infu |
Medical Equipment Held For Sale Or Rental Reserves
MedicalEquipmentHeldForSaleOrRentalReserves
|
600000 | |
| CY2017Q4 | infu |
Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
|
23369000 | |
| CY2016Q4 | infu |
Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
|
28036000 | |
| CY2017Q4 | infu |
Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
|
34077000 | |
| CY2016Q4 | infu |
Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
|
30447000 | |
| CY2017Q4 | infu |
Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
|
57928000 | |
| CY2016Q4 | infu |
Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
|
59034000 | |
| CY2017Q4 | infu |
Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
|
482000 | |
| CY2016Q4 | infu |
Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
|
551000 | |
| CY2017 | infu |
Medical Equipment In Rental Services Useful Life
MedicalEquipmentInRentalServicesUsefulLife
|
P7Y | |
| CY2017Q4 | infu |
Medical Equipment Net
MedicalEquipmentNet
|
24936000 | |
| CY2016Q4 | infu |
Medical Equipment Net
MedicalEquipmentNet
|
29678000 | |
| CY2017 | infu |
Net Operating Loss Carryforwards Limitation On Use
NetOperatingLossCarryforwardsLimitationOnUse
|
1800000 | |
| CY2017Q4 | infu |
Number Of Financial Institutions
NumberOfFinancialInstitutions
|
2 | |
| CY2017Q4 | infu |
Number Of Operating Locations
NumberOfOperatingLocations
|
6 | |
| CY2017Q4 | infu |
Remaining Preownership Net Operating Loss Carryforwards
RemainingPreownershipNetOperatingLossCarryforwards
|
4700000 | |
| CY2017Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Three
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearThree
|
31000 | |
| CY2017Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Two
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearTwo
|
30000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5516000 | |
| CY2017Q4 | infu |
Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance
|
294863 | |
| CY2017Q4 | infu |
Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
|
28000 | |
| CY2016Q4 | infu |
Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
|
22000 | |
| CY2017Q4 | infu |
Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
|
92000 | |
| CY2016Q4 | infu |
Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
|
87000 | |
| CY2017Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal Current
UnamortizedValueOfDebtIssuanceCostsPrincipalCurrent
|
28000 | |
| CY2017Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Five
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFive
|
||
| CY2017Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Four
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFour
|
31000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5315000 | |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
11385000 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
11581000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4496000 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4118000 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
92584000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
91829000 | |
| CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
204000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
131000 | |
| CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
462000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
682000 | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
6514000 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4989000 | |
| CY2015Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4737000 | |
| CY2017 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
4116000 | |
| CY2016 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
5379000 | |
| CY2017 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
28000 | |
| CY2016 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
31000 | |
| CY2017 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
5560000 | |
| CY2016 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3849000 | |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
490428 | |
| CY2016 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
90715 | |
| CY2017 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
993000 | |
| CY2016 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
||
| CY2017Q4 | us-gaap |
Assets
Assets
|
68881000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
96344000 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
17667000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
20769000 | |
| CY2017 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="width:24pt;vertical-align:top;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td style="vertical-align:top;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-size:10pt;font-family:'Times New Roman', Times, serif;"> Basis of Presentation and Nature of Operations</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the “Company”) <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. InfuSystem Inc. (“ISI”), which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program (“CHAP”) while First Biomedical, Inc. (“First Biomedical”), which is an operating subsidiary of the Company, is ISO certified.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">’s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company’s pumps are electronic infusion pumps. Smiths Medical, Inc. supplies more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the ambulatory pumps purchased by the Company. The Company has a supply agreement in place with this supplier. Certain “spot” purchases are made on the open market subject to individual negotiation.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In addition, the Company sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">, oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the small-hospital market.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company purchases new and pre-owned pole mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company’s ambulatory infusion pump management service.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.5pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).</div></div></div> | |
| CY2017 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
549000 | |
| CY2016 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
429000 | |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
505000 | |
| CY2016Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
2938000 | |
| CY2017 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
137000 | |
| CY2016 | us-gaap |
Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
|
2675000 | |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
33000 | |
| CY2016Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
2573000 | |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
547000 | |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
514000 | |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
||
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
||
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
||
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
33000 | |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
|
||
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
|
9000 | |
| CY2017Q4 | us-gaap |
Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
|
538000 | |
| CY2017 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
3100000 | |
| CY2016 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
1700000 | |
| CY2017Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
200000 | |
| CY2016Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
3500000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3469000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3398000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
818000 | |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
71000 | |
| CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2580000 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22978398 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22867335 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22780738 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22669675 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2017 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.5pt;">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party reimbursement, it is possible that management’s estimates could change in the near term, which could have a material impact on the Company’s results of operations and cash flows.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">the Company’s largest contracted payor was a national association comprised of multiple members, which in the aggregate, accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24%</div> of the Company’s net revenues from our Oncology Business and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13%</div> of our total revenues for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>respectively. For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> our next largest contracted payor, was a national association comprised of multiple members, which, in the aggregate, accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%</div> of our net revenues from our Oncology Business and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%</div> of our total revenues for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>respectively.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">the Company’s largest contracted payor was Medicare, which accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> of our net revenues from our Oncology Business and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13%</div> of our total revenues for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>respectively. Our next largest contracted payor, was a national association comprised of multiple members, which, in the aggregate, accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19%</div> of our net revenues from our Oncology Business and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13%</div> of our total revenues for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>respectively. </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.5pt;">We also contract with various other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor organizations, Medicaid, commercial Medicare replacement plans, self-insured plans and numerous other insurance carriers. Other than the payors noted above, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> other single payor represented more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party payor net revenue.</div></div></div> | |
| CY2017 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
18367000 | |
| CY2016 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
16206000 | |
| CY2017Q4 | us-gaap |
Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
|
216000 | |
| CY2017 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-73000 | |
| CY2016 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
||
| CY2017 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
88000 | |
| CY2016 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
40000 | |
| CY2017 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
45000 | |
| CY2016 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
58000 | |
| CY2017Q1 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
766650 | |
| CY2017Q2 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
766650 | |
| CY2017Q3 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
766650 | |
| CY2017Q4 | us-gaap |
Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
|
766650 | |
| us-gaap |
Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
|
577500 | ||
| CY2017Q3 | us-gaap |
Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
|
577500 | |
| CY2017Q4 | us-gaap |
Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
|
577500 | |
| CY2017 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
13830000 | |
| CY2016 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-157000 | |
| CY2017 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
15389000 | |
| CY2016 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-240000 | |
| CY2017 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
1560000 | |
| CY2016 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-83000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
15111000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
||
| CY2016Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
2675000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
||
| CY2016Q4 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
12436000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11435000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
||
| CY2015Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
||
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
62000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
62000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
||
| CY2017 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
600000 | |
| CY2016 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
700000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
6963000 | |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
6895000 | |
| CY2017 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
500000 | |
| CY2016 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
600000 | |
| CY2017 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.91 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
4402000 | |
| CY2016 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | |
| CY2017 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.91 | |
| CY2016 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.01 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-2.9389 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.3909 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-2.1749 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-1.0595 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
-0.0117 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
-0.0379 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.0037 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.0031 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.046 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0916 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
-0.3781 | |
| CY2017 | us-gaap |
Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
|
49150 | |
| CY2016 | us-gaap |
Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
|
113531 | |
| CY2014Q2 | us-gaap |
Employee Stock Ownership Plan Esop Shares Contributed To Esop
EmployeeStockOwnershipPlanESOPSharesContributedToESOP
|
200000 | |
| CY2017 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
13757000 | |
| CY2016 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-157000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
26409000 | |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
22199000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
3197000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
4649000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
2051000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
3930000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
4285000 | |
| CY2017 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
1797000 | |
| CY2016 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
1231000 | |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
25200000 | |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
24629000 | |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-364000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
162000 | |
| CY2017Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
25454000 | |
| CY2017 | us-gaap |
Gross Profit
GrossProfit
|
43361000 | |
| CY2016 | us-gaap |
Gross Profit
GrossProfit
|
44740000 | |
| CY2017Q4 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | |
| CY2017 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
1000000 | |
| CY2016 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2017 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
207000 | |
| CY2016 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
641000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-5419000 | |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-600000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5257000 | |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
236000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-5257000 | |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-364000 | |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15450000 | |
| CY2016 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-142000 | |
| CY2017 | us-gaap |
Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
|
5600000 | |
| CY2017 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
0 | |
| CY2016 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
600000 | |
| CY2017 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
139000 | |
| CY2016 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
105000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-352000 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-3146000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5445000 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4589000 | |
| CY2017 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-402000 | |
| CY2016 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
250000 | |
| CY2017 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
100000 | |
| CY2016 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
88000 | |
| CY2017 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-119000 | |
| CY2016 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-166000 | |
| CY2017 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
||
| CY2016 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
||
| CY2017Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
50923000 | |
| CY2016Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
53438000 | |
| CY2017Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
24514000 | |
| CY2016Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
31239000 | |
| CY2017 | us-gaap |
Interest Expense
InterestExpense
|
1332000 | |
| CY2016 | us-gaap |
Interest Expense
InterestExpense
|
1344000 | |
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1200000 | |
| CY2016 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1234000 | |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
1764000 | |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
2166000 | |
| CY2017Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
100000 | |
| CY2016Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
200000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
37928000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
45655000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
68881000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
96344000 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12474000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16439000 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
225000 | |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3414000 | |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3812000 | |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
974000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
4365000 | |
| CY2016Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
29216000 | |
| CY2017Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
28391000 | |
| CY2016Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
31891000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
3039000 | |
| CY2016Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
5314000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
3039000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
||
| CY2017Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
19279000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
3036000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
3037000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
25352000 | |
| CY2016Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
26577000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-8565000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
15000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1053000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5344000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
7583000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
7909000 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20707000 | |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-222000 | |
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1445000 | |
| CY2016 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1338000 | |
| CY2017 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
47173000 | |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
43766000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1326000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
191000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
181000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
695000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1225000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
747000 | |
| CY2017 | us-gaap |
Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
|
61085000 | |
| CY2016 | us-gaap |
Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
|
62210000 | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1000000 | |
| CY2016 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1000000 | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1049000 | |
| CY2016Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
949000 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
131000 | |
| CY2016Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
2872000 | |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
7000 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
66000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-113000 | |
| CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
6000 | |
| CY2017 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
38000 | |
| CY2016 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
7000 | |
| CY2017 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
58000 | |
| CY2016 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
75000 | |
| CY2017 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
||
| CY2016 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
66999000 | |
| CY2017 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
3299000 | |
| CY2016 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
5101000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
104000 | |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
168000 | |
| CY2016 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
370000 | |
| CY2017 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
192000 | |
| CY2016 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
3526000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
28866000 | |
| CY2016 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
66892000 | |
| CY2017 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
4648000 | |
| CY2016 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
3821000 | |
| CY2017 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
131000 | |
| CY2016 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
204000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6129000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6115000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1633000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1997000 | |
| CY2017 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
5641000 | |
| CY2016 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
5631000 | |
| CY2017 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
37466000 | |
| CY2017 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22739651 | |
| CY2017 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
48000 | |
| CY2016 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
151000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-61633000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-41142000 | |
| CY2017 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
9992000 | |
| CY2016 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
8287000 | |
| CY2017 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
71077000 | |
| CY2016 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
70497000 | |
| CY2017 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9779000 | |
| CY2016 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9657000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
682000 | |
| CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
462000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
2.09 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
2.76 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.35 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0069 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
350000 | |
| CY2016 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
0 | |
| CY2017 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
0 | |
| CY2017Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
120000 | |
| CY2016Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
109000 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y339D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y3D | |
| CY2017 | us-gaap |
Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
|
100000 | |
| CY2016 | us-gaap |
Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
|
100000 | |
| CY2017 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
1605000 | |
| CY2016 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-25000 | |
| CY2017 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
68958 | |
| CY2016 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
88109 | |
| CY2016 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
||
| CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
||
| CY2017 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
634000 | |
| CY2016 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
311000 | |
| CY2016 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
75000 | |
| CY2017 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
58000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
30953000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
50689000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
50320000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Use</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"> of Estimates</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.5pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, which includes contractual adjustments, accounts receivable and allowance for doubtful accounts, sales return allowances, inventory reserves, long lived assets, intangible assets valuations and income tax valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgment and estimates. Actual results could differ materially from those estimates.</div></div></div></div> | |
| CY2017 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22739651 | |
| CY2016 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22617901 | |
| CY2016 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22617901 |
